Structure Therapeutics (GPCR) Profit After Tax (2022 - 2026)

Structure Therapeutics' Profit After Tax history runs 5 years deep, the most recent figure standing at -$76.0 million for Q1 2026.

• In Q1 2026, Profit After Tax fell 62.21% year-over-year to -$76.0 million; the TTM figure through Mar 2026 stood at -$170.3 million (down 18.85% YoY), while the FY2025 annual figure was -$141.2 million, down 15.24% from the prior year.
• Profit After Tax was -$76.0 million for Q1 2026 at Structure Therapeutics, down from $33.0 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $33.0 million in Q4 2025 to a low of -$76.0 million in Q1 2026.
• Historically, Profit After Tax has averaged -$28.3 million across 5 years, with a median of -$24.5 million in 2023.
• Biggest YoY gain for Profit After Tax was 190.47% in 2025; the steepest drop was 136.85% in 2025.
• A 5-year view of Profit After Tax shows it stood at -$11.9 million in 2022, then plunged by 106.34% to -$24.5 million in 2023, then plunged by 48.88% to -$36.5 million in 2024, then surged by 190.47% to $33.0 million in 2025, then sank by 330.18% to -$76.0 million in 2026.
• The last three Profit After Tax figures came in at -$76.0 million (Q1 2026), $33.0 million (Q4 2025), and -$65.7 million (Q3 2025), per Business Quant data.